New drug duo aims to tackle stubborn hepatitis d
NCT ID NCT07128550
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This Phase 3 trial tests whether a combination of two experimental drugs, tobevibart and elebsiran, can suppress hepatitis D virus in people who are not fully controlled by the current treatment bulevirtide. About 150 adults with chronic hepatitis D will receive the combo as injections. The main goal is to see if the virus becomes undetectable in the blood after 24 weeks of treatment and stays undetectable for another 24 weeks after stopping.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VIRAL HEPATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigative Site
RECRUITINGInnsbruck, 6020, Austria
-
Investigative Site
RECRUITINGVienna, 1090, Austria
-
Investigative Site
RECRUITINGBobigny, 93009, France
-
Investigative Site
RECRUITINGClichy, 92110, France
-
Investigative Site
RECRUITINGCréteil, 94000, France
-
Investigative Site
RECRUITINGLe Chesnay, 78150, France
-
Investigative Site
RECRUITINGLimoges, 87000, France
-
Investigative Site
RECRUITINGLyon, 69004, France
-
Investigative Site
RECRUITINGMontpellier, 34295, France
-
Investigative Site
RECRUITINGPessac, 33604, France
-
Investigative Site
RECRUITINGRennes, 35033, France
-
Investigative Site
RECRUITINGToulouse, 31059, France
-
Investigative Site
RECRUITINGVillejuif, 94804, France
-
Investigative Site
RECRUITINGBerlin, 13353, Germany
-
Investigative Site
RECRUITINGEssen, 45147, Germany
-
Investigative Site
RECRUITINGFrankfurt am Main, 60590, Germany
-
Investigative Site
RECRUITINGHanover, 30625, Germany
-
Investigative Site
RECRUITINGBergamo, 24127, Italy
-
Investigative Site
RECRUITINGFoggia, 71122, Italy
-
Investigative Site
RECRUITINGMilan, 20089, Italy
-
Investigative Site
RECRUITINGMilan, 20122, Italy
-
Investigative Site
RECRUITINGPisa, 56124, Italy
-
Investigative Site
RECRUITINGTorino, 10122, Italy
-
Investigative Site
RECRUITINGTorino, 10126, Italy
-
Investigative Site
RECRUITINGBucharest, 021105, Romania
-
Investigative Site
RECRUITINGBucharest, 022328, Romania
-
Investigative Site
RECRUITINGBucharest, 030303, Romania
-
Investigative Site
RECRUITINGCraiova, 200073, Romania
-
Investigative Site
RECRUITINGBarcelona, 08035, Spain
-
Investigative Site
RECRUITINGBarcelona, 08036, Spain
-
Investigative Site
RECRUITINGMadrid, 28007, Spain
-
Investigative Site
RECRUITINGMadrid, 28046, Spain
-
Investigative Site
RECRUITINGSantander, 39008, Spain
-
Investigative Site
RECRUITINGLondon, E1 1FR, United Kingdom
-
Investigative Site
RECRUITINGLondon, SE5 9NU, United Kingdom
-
Investigative Site
RECRUITINGLondon, W2 1NY, United Kingdom
-
Investigative Site
RECRUITINGManchester, M8 5RB, United Kingdom
-
Investigative Site
RECRUITINGNottingham, NG7 2UH, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tobevibart and Elebsiran (two drugs given as injections)
What this could lead to
If successful, this combination could offer a new treatment option for people with chronic hepatitis D who are not responding well to current therapy.
What could go wrong
This is an early Phase 3 trial with only 150 participants, so results may not apply to everyone. The drugs may cause side effects or fail to clear the virus long-term.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.